2015
New onset executive function difficulties at menopause: a possible role for lisdexamfetamine
Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, Appleby DH, Iannelli C, Sammel MD, Brown TE. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology 2015, 232: 3091-3100. PMID: 26063677, PMCID: PMC4631394, DOI: 10.1007/s00213-015-3953-7.Peer-Reviewed Original ResearchConceptsBrown Attention-Deficit Disorder ScaleExecutive function difficultiesExecutive functionAttention Deficit Disorder ScaleLDX treatmentObjective cognitive functionMemory taskVerbal memoryVerbal recallCognitive measuresParagraph recallLifetime ADHDCognitive functionCognitive declineDisorder ScaleSubjective measuresMenopausal womenSubscale scoresLisdexamfetamineObjective measuresRecallEarly postmenopausal womenSystolic blood pressureCross-over studyHealthy menopausal women
2013
A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression
Hantsoo L, Ward-O’Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 2013, 231: 939-948. PMID: 24173623, PMCID: PMC3945214, DOI: 10.1007/s00213-013-3316-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepression, PostpartumDouble-Blind MethodFemaleHumansPlacebosSelective Serotonin Reuptake InhibitorsSertralineConceptsDSM-IV criteriaDouble-blind placebo-controlled trialSelective serotonin reuptake inhibitor sertralineSerotonin reuptake inhibitor sertralineClinical Global Impression scoresHamilton Depression Rating ScaleRating ScaleStrict DSM-IV criteriaDouble-blind trialPlacebo-controlled studyPlacebo-controlled trialHamilton Anxiety Rating ScaleMonths of deliverySubset of womenPrimary outcome variableWeeks of childbirthDepression Rating ScaleGlobal Impression scoresGreater response rateMajor depressive disorderOnset of depressionAnxiety Rating ScaleSignificant groupSertraline 50Remission rate